VCNXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (29 4月 2024 @ 23:43):

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs...

Stats
本日の出来高	1 978.00
平均出来高	13 896.00
時価総額	8.64M
EPS	$0 ( 2024-04-02 )
次の収益日	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.140
ATR14	$0.226 (3.73%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Friedberg Albert	Buy	282	Common Stock
2024-03-28	Zauderer Maurice	Buy	38 610	Common Stock
2024-03-28	Zauderer Maurice	Buy	38 610	Warrant (Right to Buy)
2024-03-28	Friedberg Albert	Buy	102 960	Common Stock
2024-03-28	Friedberg Albert	Buy	102 960	Warrant (Right to Buy)

INSIDER POWER
99.87
Last 100 transactions
Buy: 40 266 892 \| Sell: 9 809 782

Vaccinex Inc 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Vaccinex Inc 財務諸表

Annual	2023
収益:	$570 000
総利益:	$451 000 (79.12 %)
EPS:	$-43.68

FY	2023
収益:	$570 000
総利益:	$451 000 (79.12 %)
EPS:	$-43.68

FY	2022
収益:	$100 000
総利益:	$-107 000 (-107.00 %)
EPS:	$-97.59

FY	2021
収益:	$900 000
総利益:	$900 000 (100.00 %)
EPS:	$-1.191

Financial Reports:

No articles found.

Vaccinex Inc

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.